US4523271090 - Common Stock - After market: 213.86 0 (0%)
EU antitrust regulators on Monday proposed measures for U.S. life sciences company Illumina to unwind its acquisition of biotech firm Grail , three months after blocking the deal on concerns that it would hurt competition. Illumina completed the takeover of Grail in August 2021, without securing European Union regulatory approval. The European Commission said in a September veto decision that the company failed to offer adequate remedies to allay its worries and opened a separate case to force Illumina to unravel the deal.
The European Commission said Illumina will have to restore Grail’s independence and return it to the same level that existed before the acquisition.
EU antitrust regulators on Monday sent a charge sheet to U.S. life sciences company Illumina outlining proposed measures to unwind its acquisition of Grail, three months after they blocked the deal on concerns that it would hurt competition. Illumina completed the deal in August last year without first waiting for EU regulatory approval. The European Commission in its September decision said the company failed to offer adequate remedies to allay its worries.
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Evercore ISI...
Gene sequencing company Illumina (ILMN) announced it is reducing about 5% of its global employees in response to the current macro environment
Illumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the genetic sequencing equipment maker's business.
Illumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the genetic sequencing equipment maker's business. The company, which is in the process of launching its next-generation NovaSeq X DNA sequencing systems, has over 9,100 employees globally, according to its website.
A mixed jobs report and heavy earnings swung stocks.
Illumina posted a wide miss for its full-year adjusted earnings outlook, leading shares to tumble after hours.
Revenue of $1.12 billion for Q3 2022, up 1% from Q3 2021, and up 3% on a constant currency basis GAAP diluted loss per share of $(24.26) for Q3 2022, compared...
Although "Big Tech" is currently struggling, but there are still many good top tech stocks to buy at this point.
EU antitrust regulators on Friday renewed interim measures ordering U.S. life sciences company Illumina to keep Grail as a separate entity pending an order to unwind the takeover completed before the deal had been approved.
EU antitrust regulators on Friday renewed interim measures ordering U.S. life sciences company Illumina to keep Grail as a separate entity pending an order to unwind the takeover completed before the deal had been approved. The interim order, which was due to expire at the end of the month, was issued by the competition enforcer last year after Illumina jumped the gun and acquired Grail before securing the EU green light. "The European Commission has renewed and adjusted, under the EU Merger Regulation, the interim measures that ensure that Illumina and GRAIL remain separate following the Commission's decision to block the merger," the EU watchdog said in a statement.
Bionano's stock price movements have little to do with its successes.
PacBio says its latest technology will halve the cost of sequencing using its products, which could expand its market.
UST releases high-throughput solution enabling second-generation short-read sequencers to produce long-range results in greater capacity.CARLSBAD, Calif. - Oct. 24, 2022 - PRLog -- Universal Sequencing Technology Corporation (UST), a global leader in genomic sequencing innovations, announces today, October 24th, 2022, the release of 96-well plate TELL-Seq™ Library Multiplexing Primers for high throughput sample indexing.With this expanded indexing capability, our customers/TELL-seq users can pool many samples in one sequencing run, significantly reducing NGS library preparation and sequencing costs. The 96-well plate multiplexing primers include the 10-base indexes that will ensure their compatibility across different Illumina sequencing platforms providing the most stringent nucleotide balance in each sequencing cycle to achieve the optimal performance and highest sequencing quality. The 10-base index primers come in a 96-well plate format with a pierceable seal, making their use with NGS library preparation automation platforms convenient and easy.When used in combination with the UST's TELL-Seq High Throughput kit, researchers will be able to take advantage of the ultra-long linked-read results to provide unparalleled genomic information up to and exceeding 200Kb gDNA fragments with applications ranging from WGS, phasing, SV detection, metagenomics, and more for small, medium, and large genomes.With TELL-Seq NGS technology, we've made library preparation easy. Our products effectively improve performance, time, and budget across a broad range of sample types with a proven track record.Dr. Zhoutao (Tom) Chen, Chief Scientific Officer of UST, stated, "We are further streamlining the TELL-seq workflow by simplifying sample preparation and scaling up throughput in response to increased customer demands."UST's TELL-Seq is a patent-pending transposase-based linked-read library preparation technology that enables short-read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce long-range sequencing results (averaging linked-read molecule length greater than 40kb up to and exceeding 200kb). With a simple workflow, a sequencing-ready library can be prepared in PCR tubes in about 3 hours, cost-effectively, and with minimal lab equipment.Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, stated, "TELL-Seq Linked-Long-Read Library technology provides valuable solutions that enrich the short read sequencers by enabling them to produce the long-range results ranging to 200kb and more."ABOUT USTUniversal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 provisional patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd-generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.www.universalsequencing.com
/PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), un leader mondial dans le domaine du séquençage de l'ADN et des technologies basées sur les réseaux, et...
Illumina is the dominant player in gene sequencing.
/PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company,...
London, UK -- (SBWIRE) -- 10/18/2022 -- The latest publication titled Companion Diagnostics – Thematic Research has been added to GlobalData Plc report store. Companion diagnostics (CDx) are molecular assays that measure levels of proteins, genes, or specific mutations to reveal a specific, efficacious therapy for an individual's condition. CDx are a form of personalized, stratified, and precision medicine due to which a patient's treatment will become increasingly individualized.
This press release was orginally distributed by SBWire